SURFACE LOGIX INC. TO PRESENT AT THE 2007 BIO INVESTOR FORUM

BOSTON, Mass. (October 3, 2007) – Surface Logix, Inc. announced that Jim Mahoney, President and Chief Executive Officer, will present an update of the company’s drug development pipeline at the 2007 BIO Investor Forum on October 10, 2007 at 1:45 PM PST from The Palace Hotel in San Francisco.

Surface Logix currently has two programs in human clinical trials with a third program approaching an IND filing. Mr. Mahoney will discuss the latest results for SLx-2101 and SLx-4090. SLx-2101, a second generation PDE5 inhibitor designed to address cardiovascular indications, is currently in two separate Phase 2a trials, one in hypertension and the other in Raynaud’s Syndrome. SLx-4090, a first-in-class enterocyte specific MTP inhibitor for the treatment of dyslipidemia and potentially other indications, will soon be completing a Phase 2a study.

About Surface Logix, Inc.
Surface Logix, Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) with superior intrinsic drug-like properties that are clearly differentiated from competitive products. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com

Contact:
Leland Webster, Ph.D., M.B.A.
Surface Logix Inc.
Vice President, Corporate Development
617.746.8520

Media:
Sarah Cavanaugh
MacDougall Biomedical Communications Inc.
scavanaugh@macbiocom.com
508.647.0209